Your browser doesn't support javascript.
Differential neutralization and inhibition of SARS-CoV-2 variants by antibodies elicited by COVID-19 mRNA vaccines.
Wang, Li; Kainulainen, Markus H; Jiang, Nannan; Di, Han; Bonenfant, Gaston; Mills, Lisa; Currier, Michael; Shrivastava-Ranjan, Punya; Calderon, Brenda M; Sheth, Mili; Mann, Brian R; Hossain, Jaber; Lin, Xudong; Lester, Sandra; Pusch, Elizabeth A; Jones, Joyce; Cui, Dan; Chatterjee, Payel; Jenks, M Harley; Morantz, Esther K; Larson, Gloria P; Hatta, Masato; Harcourt, Jennifer L; Tamin, Azaibi; Li, Yan; Tao, Ying; Zhao, Kun; Lacek, Kristine; Burroughs, Ashley; Wang, Wei; Wilson, Malania; Wong, Terianne; Park, So Hee; Tong, Suxiang; Barnes, John R; Tenforde, Mark W; Self, Wesley H; Shapiro, Nathan I; Exline, Matthew C; Files, D Clark; Gibbs, Kevin W; Hager, David N; Patel, Manish; Halpin, Alison L; McMullan, Laura K; Lee, Justin S; Xia, Hongjie; Xie, Xuping; Shi, Pei-Yong; Davis, C Todd.
  • Wang L; COVID-19 Emergency Response, Centers for Disease Control and Prevention, Atlanta, GA, USA.
  • Kainulainen MH; COVID-19 Emergency Response, Centers for Disease Control and Prevention, Atlanta, GA, USA.
  • Jiang N; COVID-19 Emergency Response, Centers for Disease Control and Prevention, Atlanta, GA, USA.
  • Di H; COVID-19 Emergency Response, Centers for Disease Control and Prevention, Atlanta, GA, USA.
  • Bonenfant G; COVID-19 Emergency Response, Centers for Disease Control and Prevention, Atlanta, GA, USA.
  • Mills L; COVID-19 Emergency Response, Centers for Disease Control and Prevention, Atlanta, GA, USA.
  • Currier M; COVID-19 Emergency Response, Centers for Disease Control and Prevention, Atlanta, GA, USA.
  • Shrivastava-Ranjan P; COVID-19 Emergency Response, Centers for Disease Control and Prevention, Atlanta, GA, USA.
  • Calderon BM; COVID-19 Emergency Response, Centers for Disease Control and Prevention, Atlanta, GA, USA.
  • Sheth M; COVID-19 Emergency Response, Centers for Disease Control and Prevention, Atlanta, GA, USA.
  • Mann BR; COVID-19 Emergency Response, Centers for Disease Control and Prevention, Atlanta, GA, USA.
  • Hossain J; COVID-19 Emergency Response, Centers for Disease Control and Prevention, Atlanta, GA, USA.
  • Lin X; COVID-19 Emergency Response, Centers for Disease Control and Prevention, Atlanta, GA, USA.
  • Lester S; COVID-19 Emergency Response, Centers for Disease Control and Prevention, Atlanta, GA, USA.
  • Pusch EA; COVID-19 Emergency Response, Centers for Disease Control and Prevention, Atlanta, GA, USA.
  • Jones J; COVID-19 Emergency Response, Centers for Disease Control and Prevention, Atlanta, GA, USA.
  • Cui D; COVID-19 Emergency Response, Centers for Disease Control and Prevention, Atlanta, GA, USA.
  • Chatterjee P; COVID-19 Emergency Response, Centers for Disease Control and Prevention, Atlanta, GA, USA.
  • Jenks MH; COVID-19 Emergency Response, Centers for Disease Control and Prevention, Atlanta, GA, USA.
  • Morantz EK; COVID-19 Emergency Response, Centers for Disease Control and Prevention, Atlanta, GA, USA.
  • Larson GP; COVID-19 Emergency Response, Centers for Disease Control and Prevention, Atlanta, GA, USA.
  • Hatta M; COVID-19 Emergency Response, Centers for Disease Control and Prevention, Atlanta, GA, USA.
  • Harcourt JL; COVID-19 Emergency Response, Centers for Disease Control and Prevention, Atlanta, GA, USA.
  • Tamin A; COVID-19 Emergency Response, Centers for Disease Control and Prevention, Atlanta, GA, USA.
  • Li Y; COVID-19 Emergency Response, Centers for Disease Control and Prevention, Atlanta, GA, USA.
  • Tao Y; COVID-19 Emergency Response, Centers for Disease Control and Prevention, Atlanta, GA, USA.
  • Zhao K; COVID-19 Emergency Response, Centers for Disease Control and Prevention, Atlanta, GA, USA.
  • Lacek K; COVID-19 Emergency Response, Centers for Disease Control and Prevention, Atlanta, GA, USA.
  • Burroughs A; COVID-19 Emergency Response, Centers for Disease Control and Prevention, Atlanta, GA, USA.
  • Wang W; COVID-19 Emergency Response, Centers for Disease Control and Prevention, Atlanta, GA, USA.
  • Wilson M; COVID-19 Emergency Response, Centers for Disease Control and Prevention, Atlanta, GA, USA.
  • Wong T; COVID-19 Emergency Response, Centers for Disease Control and Prevention, Atlanta, GA, USA.
  • Park SH; COVID-19 Emergency Response, Centers for Disease Control and Prevention, Atlanta, GA, USA.
  • Tong S; COVID-19 Emergency Response, Centers for Disease Control and Prevention, Atlanta, GA, USA.
  • Barnes JR; COVID-19 Emergency Response, Centers for Disease Control and Prevention, Atlanta, GA, USA.
  • Tenforde MW; COVID-19 Emergency Response, Centers for Disease Control and Prevention, Atlanta, GA, USA.
  • Self WH; Vanderbilt University, Nashville, TN, USA.
  • Shapiro NI; Harvard University, Cambridge, MA, USA.
  • Exline MC; Ohio State University, Columbus, OH, USA.
  • Files DC; Wake Forest Baptist Medical Center, Winston-Salem, NC, USA.
  • Gibbs KW; Wake Forest Baptist Medical Center, Winston-Salem, NC, USA.
  • Hager DN; Johns Hopkins University, Baltimore, MD, USA.
  • Patel M; COVID-19 Emergency Response, Centers for Disease Control and Prevention, Atlanta, GA, USA.
  • Halpin AL; COVID-19 Emergency Response, Centers for Disease Control and Prevention, Atlanta, GA, USA.
  • McMullan LK; COVID-19 Emergency Response, Centers for Disease Control and Prevention, Atlanta, GA, USA.
  • Lee JS; COVID-19 Emergency Response, Centers for Disease Control and Prevention, Atlanta, GA, USA.
  • Xia H; University of Texas Medical Branch, Galveston, TX, USA.
  • Xie X; University of Texas Medical Branch, Galveston, TX, USA.
  • Shi PY; University of Texas Medical Branch, Galveston, TX, USA.
  • Davis CT; COVID-19 Emergency Response, Centers for Disease Control and Prevention, Atlanta, GA, USA.
Nat Commun ; 13(1): 4350, 2022 07 27.
Article in English | MEDLINE | ID: covidwho-1960369
ABSTRACT
The evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has resulted in the emergence of new variant lineages that have exacerbated the COVID-19 pandemic. Some of those variants were designated as variants of concern/interest (VOC/VOI) by national or international authorities based on many factors including their potential impact on vaccine-mediated protection from disease. To ascertain and rank the risk of VOCs and VOIs, we analyze the ability of 14 variants (614G, Alpha, Beta, Gamma, Delta, Epsilon, Zeta, Eta, Theta, Iota, Kappa, Lambda, Mu, and Omicron) to escape from mRNA vaccine-induced antibodies. The variants show differential reductions in neutralization and replication by post-vaccination sera. Although the Omicron variant (BA.1, BA.1.1, and BA.2) shows the most escape from neutralization, sera collected after a third dose of vaccine (booster sera) retain moderate neutralizing activity against that variant. Therefore, vaccination remains an effective strategy during the COVID-19 pandemic.
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Type of study: Prognostic study Topics: Vaccines / Variants Limits: Humans Language: English Journal: Nat Commun Journal subject: Biology / Science Year: 2022 Document Type: Article Affiliation country: S41467-022-31929-6

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Type of study: Prognostic study Topics: Vaccines / Variants Limits: Humans Language: English Journal: Nat Commun Journal subject: Biology / Science Year: 2022 Document Type: Article Affiliation country: S41467-022-31929-6